SCHEMBL5202698

SCHEMBL5202698

COc1cc2c(Oc3ccc(N)c(Cl)c3)ncnc2cc1OCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.61
FLT4 P35916 5/20 0.59
CSF1R P07333 2/20 0.59
PDGFRB P09619 2/20 0.59
FLT3 P36888 1/20 0.59
EGFR P00533 3/20 0.57
LCK P06239 2/20 0.57
IRAK1 P51617 1/20 0.56
IRAK4 Q9NWZ3 1/20 0.56
RET P07949 1/20 0.54
KIF5B P33176 1/20 0.54
KIT P10721 2/20 0.52
PDGFRA P16234 2/20 0.52
KDM1A O60341 1/20 0.51
FLT1 P17948 3/20 0.51
BRAF P15056 1/20 0.49
AURKA O14965 1/20 0.48
MET P08581 1/20 0.48
TEK Q02763 1/20 0.48
AURKB Q96GD4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31616965 0.89 KDR (0.74) KDRFLT4CSF1RPDGFRBFLT3
SCHEMBL4668514 0.89 KDR (0.74) KDRFLT4CSF1RPDGFRBFLT3
SCHEMBL4466873 0.86 CSF1R (0.68) KDRFLT4CSF1RPDGFRBFLT3
SCHEMBL30406755 0.86 CSF1R (0.68) KDRFLT4CSF1RPDGFRBFLT3
SCHEMBL5208322 0.86 PDGFRB (0.55) KDRPDGFRBEGFRPDGFRAMET
SCHEMBL15962830 0.86 KDR (0.63) KDRFLT4EGFRLCKRET
SCHEMBL4023315 0.85 PDGFRB (0.75) KDRFLT4CSF1RPDGFRBFLT3
SCHEMBL1011381 0.85 PDGFRB (0.66) KDRFLT4CSF1RPDGFRBFLT3
SCHEMBL1016085 0.85 PDGFRB (0.66) KDRFLT4CSF1RPDGFRBFLT3
SCHEMBL4359665 0.84 CSF1R (0.81) KDRFLT4CSF1RPDGFRBFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1384712-B1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BREWERY (JP) 2007-03-07 EP disclosed
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-02-01 US disclosed
US-7169789-B2 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-01-30 US disclosed
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-10-21 US disclosed
US-6797823-B1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-09-28 US disclosed
EP-1384712-A1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BEER KABUSHIKI KAISHA (JP) 2004-01-28 EP disclosed
EP-1153920-B1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BREWERY (JP) 2003-10-29 EP disclosed
EP-1153920-A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BEER KABUSHIKI KAISHA (JP) 2001-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives CYTH3, NQO2, NRAS KDR 2466/4885FLT4 2496/4885CSF1R 1771/4885
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives RABL3, NRAS, CYTH3 KDR 3106/4885FLT4 2872/4885CSF1R 2795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.